ArticleDiagnostic and interventional radiology (Ankara, Turkey)2026
Texture analysis enhances diagnostic accuracy of lesions scored as 5 in the Prostate Imaging Reporting and Data System in magnetic resonance imaging.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the Editor: comments on the diagnostic value of ADC texture analysis in PI-RADS 5 lesions.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstatitis is frequently observed in false-positive lesions scored as 5 in the Prostate Imaging Reporting and Data System (PI-RADS), necessitating improved diagnostic tools. This study investigated the potential of magnetic resonance imaging (MRI) texture analysis of apparent diffusion coefficient (ADC) sequences to enhance the differentiation of prostatitis from prostate cancer (PCa) in PI-RADS 5 lesions.
methodsThis retrospective study enrolled patients undergoing 3.0-T MRI with lesions scored as PI-RADS 5. Lesions were manually delineated on ADC maps, and texture features were extracted using FireVoxel. Clinical data and ADC texture parameters were collected. The diagnostic performance [area under the curve (AUC), sensitivity (SEN), specificity (SPE), positive predictive value (PPV), negative predictive value (NPV)] of the clinical data, ADC texture, and a combined model were calculated and compared using the DeLong test.
resultsThe final cohort included 189 patients with 189 PI-RADS 5 lesions (164 PCa, 25 prostatitis). The combined model, incorporating clinical indicators (age, prostate-specific antigen density) and ADC texture parameters (signal coefficient of variation, ADC percentile), revealed the optimal diagnostic performance: SEN 98.7%, SPE 60.0%, PPV 97.9%, NPV 71.6%, and AUC 93.1%. Bootstrap resampling verified the robustness of the model. Decision curve analysis indicated an improved net benefit with the combined model for guiding biopsy decisions.
conclusionADC imaging texture parameters are valuable for the differential diagnosis of prostatitis from lesions scored as PI-RADS 5. Their combination with clinical indicators substantially improves diagnostic performance, providing valuable information to facilitate surgical decision-making and potentially reduce unnecessary biopsies. CLINICAL SIGNIFICANCE: This study addresses a critical limitation of the current PI-RADS system, which exhibits a notable rate of false positives in high-risk PI-RADS 5 lesions. By demonstrating the added value of quantitative ADC texture analysis in this specific diagnostic challenge, this research offers a practical and potentially translatable approach to reducing the number of unnecessary biopsies for PI-RADS 5 lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.